yoga, meditation, and other therapies after the course. And we have also included a provocative, hypothesisgenerating review of the potential use of acupuncture for chemotherapy-related cognitive difficulties from Michael Johnston, Kit Hui, and other colleagues associated with the Center for East-West Medicine at UCLA.
Parallel to the evidence-based hierarchy of clinical trials is the world of laboratory studies, which this issue also features. A group of studies in this issue hails from some of our frequent foreign contributors, natural product scientists in India. Several Indian groups are working on plant products with the potential to ameliorate the side effects of conventional therapies or to assist cancer patients with management of common cancer-related symptoms. Drs Sheeja and Kuttan from the Amala Cancer Research Centre discuss the impact of Andrographis paniculata, so-called Kan Jang, on immune function in tumor-bearing mice. Kan Jang is notable for several positive human trials in management of upper respiratory infections, and it is interesting to see a new potential application in the field of cancer. Dr Venkatesh and colleagues at Kasturba Medical College examined the ability of the ancient Indian remedy Aegle marmelos, "Bael," to inhibit doxorubicin-induced genetic damage. Dr Arora Rajesh and colleagues from the Institute of Nuclear Medicine in Delhi recount a study of the effects of Podophyllum hexandrum (a source of compounds used in the synthesis of the antineoplastic etoposide) on radiation damage to the hemopoietic system.
We are publishing a series of such detailed experimental studies of plant extracts that have potential in cancer symptom relief, as well as amelioration of conventional medical side effects. Plants may become quite important in the development of new chemoprotectors and radioprotectors that are inexpensive and lacking in the major side effects of some current chemoprotectors and radioprotectors (eg, amifostine). These plant extracts, many of which have anticancer activities on their own, are an intriguing subject. For many observers, there is ongoing controversy about whether antioxidant substances might interfere with chemotherapy or radiation treatment. Although most of these plants have antioxidant activities, the presence of independent anticancer activities may change the therapeutic profile they offer.
But in the midst of highly refined systematic reviews, clinical trials, and carefully focused lab studies, we also present 4 articles dealing with case studies-the bottom of the evidence hierarchy. Even with all the drawbacks of case studies as evidence for medical decision making, case studies like the ones in this issue add something unique and valuable to integrative medicine as a whole. The first case study is actually associated with a clinical trial. It is the report, by Aaron Katz and colleagues at Columbia University, of the first patient to complete their clinical trial of the multicomponent herbal formula Zyflamend ® in high-grade prostatic intraepithelial neoplasia (HGPIN). Seeing this study in the light of several other recent studies in prostate cancer and HGPIN that show the abilities of phytochemicals, plant extracts, and diet change to impact prostate cancer is truly exciting. My own clinical experience with individualized diet, supplement, and lifestyle programs in metastatic prostate cancer certainly suggests this encouraging outcome.
A second case report concerns regression of recurrent malignant melanoma in a patient who refused conventional treatment for metastases, undertaking a self-prescribed program of antioxidant supplements, green tea, pineapple, and exercise. Melanoma, a cancer that is more sensitive to immune system attack than most, does have a record of spontaneous remission. However, Dr Agnieska Michael and colleagues at Guys' and St. Thomas' Hospital in London point out that remission of metastases is quite rare and that in view of their nontoxic nature and the lack of viable options faced by many patients, it is unnecessary to discourage programs such as the foods and supplements taken by this patient.
A case series of patients in the United Kingdom using the Gerson treatment by Alex Molassiotis of the University of Manchester represents a more ambitious and complicated program. The Gerson treatment involves diet changes, consuming large amounts of fruit and vegetable juices, and several natural supplements or medications. The authors set out to duplicate as closely as possible the procedures of the National Cancer Institute's Best Case Series program. Lacking funding and without the required diversity of clinical collaborators, they could not implement the independent review of pathology and tumor response involved in the Best Case Series. Still, the article does present a series in which instances of tumor regression or prolonged survival without use of conventional treatment are clearly obvious. This type of analysis is a first step in preparing for outcomes monitoring and interventional trials.
Our final case report is of an even more complicated treatment. Tai Lahans, an acupuncturist in Seattle, gives a detailed account of her therapy with a colon cancer patient. The patient was simultaneously undergoing conventional cancer treatment at a wellknown cancer center, and she has followed him for several years since completion of conventional treatment. Lahans draws on traditional Chinese herbal medicine, as well as the current Chinese literature, which includes many clinical studies on the use of herbal formulas alongside conventional therapies. She treated the patient with a series of different Chinese herbal formulas, each adapted to the particular challenges of conventional treatment. The patient also made major changes in diet and lifestyle and continues healthy today. A particularly interesting aspect of this article is the thorough discussion of the principles of TCM diagnosis and its explanation of some of the unique terminology of TCM-especially terms such as Wind and Damp Heat that, as Lahans says, make some Western doctors feel like TCM diagnoses read "more like a weather report than a medical diagnosis."
What is particularly interesting about these case reports, and is relevant to a topic that has lately been on the minds of ICT staff, is the complexity of the treatment regimens involved. A multiherb formula, special foods and a supplement, a diet and supplement regimen, and a series of multicomponent Chinese herbal formulas given in conjunction with conventional treatment represent an increasing gradient of complexity in integrative treatment. A cursory look at the current funding portfolio of the National Center for Complementary and Alternative Medicine (NCCAM), or at that of the Office of Cancer Complementary and Alternative Medicine (OCCAM), is enough to convince one that complex treatments such as these case reports represent are not likely to get much government funding anytime soon. The studies funded by NCCAM and OCCAM are, in fact, really solid science. They focus on specific treatments administered to specific populations with well-defined outcome variables and, as such, are likely to increase the quality and quantity of science on integrative medicine.
But what they are not is studies of complex, whole systems such as those exemplified by our case reports. The theory of whole systems research was the major theme of our previous issue (December 2006) . The National Institutes of Health funding portfolios remind us that whole systems research is certainly in its infancy and has not yet reached a level of being acceptable to review panels and funding agencies. But the truth is that most CAM practitioners do use complex whole systems. Thus, most patients in integrative care are actually receiving a variety of treatments-not a single therapy. Examining therapies one at a time not only provides an unrealistic look at patients' experiences, it may also miss the potential for fruitful synergies among the various formulas and therapies. We have, evidently, a long way to go before realistic research will be done on these systems, at least with government funding. Publishing case reports of outcomes of complicated interventions is a critical step in making the need for this research more compelling to the scientific community. We hope to continue receiving welldocumented and scientifically grounded case reports from integrative centers in the future.
As we begin a new year of the journal, it is time to acknowledge the peer reviewers who contributed their skills to the quality of this publication during 2006. Without the work of reviewers, the quality of scientific publication as a whole would drop precipitously. It is thus my pleasure to thank the following reviewers:
